Liquidia (LQDA) said Friday the US Food and Drug Administration approved Yutrepiatm for patients with pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.
The approval was based on the findings of a phase 3 trial that evaluated the prostacyclin analog's effectiveness in facilitating better exercise ability, according to a statement. The candidate was recorded as safe and well-tolerated.
An argument on a motion filed by United Therapeutics (UTHR) for a restraining order and preliminary injunction to block Liquidia from launching Yutrepia was held on May 20. The motion is pending in court, the company said.
Shares were up 0.8% after resuming trade following a trade halt.
Price: 15.51, Change: -0.05, Percent Change: -0.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.